Improvement in Radiomic Features Following Bridging Therapy is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome.
Saved in:
| Title: | Improvement in Radiomic Features Following Bridging Therapy is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome. |
|---|---|
| Authors: | Hubbeling, H.G.1 (AUTHOR), Leithner, D.2 (AUTHOR), Silverman, E.A.3 (AUTHOR), Flynn, J.4 (AUTHOR), Devlin, S.4 (AUTHOR), Shah, G.L.5 (AUTHOR), Fregonese, B.3 (AUTHOR), Bedmutha, A.2 (AUTHOR), Boardman, A.5 (AUTHOR), Dahi, P.B.5 (AUTHOR), Lin, R.J.5 (AUTHOR), Park, J.H.5 (AUTHOR), Scordo, M.6 (AUTHOR), Salles, G.5 (AUTHOR), Yahalom, J.3 (AUTHOR), Palomba, M.L.5 (AUTHOR), Schoder, H.2 (AUTHOR), Perales, M.A.5 (AUTHOR), Shouval, R.5 (AUTHOR), Imber, B.S.7 (AUTHOR) |
| Source: | International Journal of Radiation Oncology, Biology, Physics. 2024 Supplement, Vol. 120 Issue 2, pS66-S66. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 03603016 |
|---|---|
| DOI: | 10.1016/j.ijrobp.2024.07.111 |
